Why Did CVS, URGN, CCK Stocks Hit 52-Week Highs Today?
Investors showed confidence in healthcare improvements, strong biotech patents, and rising packaging demand.
Stocktwits
More News
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
Key PointsAccording to this Form 4 filing, the CMO of UroGen Pharma sold 10,000 shares at $40.00 per share, totaling $400,000 in transaction proceeds...
Nasdaq News: Markets
Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?
Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
UroGen Pharma Reaches Analyst Target Price
In recent trading, shares of UroGen Pharma Ltd (Symbol: URGN) have crossed above the average analyst 12-month target price of $36.88, changing hands for $37.94/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on va...
Nasdaq News: Markets
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?
Key Points10,000 shares were sold for a transaction value of ~$350,000 at a weighted average price of around $35.01 per share on June 22, 2026...
Nasdaq News: Markets
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares...
Yahoo! Finance: News
IBRX and the BCG Shortage: Deals That Could Expand Demand
ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.
Zacks
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
Key PointsSuperstring Capital sold 330,983 shares of UroGen Pharma Ltd last quarter; the estimated transaction value was $6.64 million based on quarterly average pricing...
Nasdaq News: Markets
Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
Urogen Pharma (NASDAQ:URGN - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.01. The company had revenue of $50.96 million for the quarter, compared to analyst...